Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Lttl Review
Before the pricing, the shipping or the commission: if you take an antidepressant, there is one product on this menu to ask about.
Lttl
Ask About The Methylene BlueSafety first, and we earn nothing for it: Lttl lists "Methylene Blue — Cognitive & mitochondrial". Methylene blue inhibits monoamine oxidase A, and FDA's Drug Safety Communication of 20 October 2011 warned of serious, sometimes fatal serotonin syndrome when it is combined with SSRIs, SNRIs, tricyclics or MAOIs. Antidepressant use is common in this population. Ask before anything is dispensed.
In fairness, on dose: the adverse events FDA described were largely at intravenous doses of 1 to 8 mg/kg during surgery, mostly alongside an SSRI, SNRI or clomipramine. A low oral consumer dose is not that exposure and we will not pretend it is — but the mechanism does not vanish at lower doses, and the screening question is free.
Injectable glutathione has its own history: FDA warned in 2018 that injectable skin lightening products may be unsafe, reported in February 2019 that seven patients suffered adverse events from a compounded L-glutathione injection with potentially high endotoxin levels, and warned compounders against using dietary-supplement-grade glutathione for sterile injectables. Selling it as "antioxidant support" does not answer a manufacturing concern.
Affiliate disclosure: This programme pays GLP1Drugs.org $375.00 on semaglutide and $375.00 on tirzepatide SKUs — the largest GLP-1 commission we have been offered — plus $225.00 on NAD+ and sermorelin, $140.00 on glutathione, $125.00 on B12 and $20.00 otherwise. Across this batch the typical commission has been a few dollars. Weigh that against every enthusiastic review of this company you read, including ours. Verified 8 August 2026.
Visit LttlOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
2011
FDA Warning On Methylene Blue
7
Patients Harmed By Compounded Glutathione
$375
Our Fee Per GLP-1 Sign-Up
$0
What The Safety Advice Earns Us
What We Verified
Product list read from Lttl's own homepage; the safety history from published FDA communications; the commission schedule from the programme terms we work under.
Methylene Blue Carries A Documented Interaction Warning
FDA issued a Drug Safety Communication on 20 October 2011 warning of serious, sometimes fatal serotonin syndrome when methylene blue is combined with serotonergic psychiatric medicines — SSRIs, SNRIs, tricyclics and MAOIs. Both methylene blue and linezolid inhibit monoamine oxidase A, the enzyme that breaks down serotonin
Lttl Sells It As A Cognitive Product
Their homepage lists "Methylene Blue — Cognitive & mitochondrial" under needle-free longevity products, alongside NAD+ nasal spray and oral liposomal NAD+. Antidepressant use is common in the population buying GLP-1s, which makes this the first question to ask, not the last
In Fairness, The Reported Cases Were High-Dose Intravenous
The adverse events FDA described typically occurred at intravenous doses of 1 to 8 mg/kg during parathyroid surgery, mostly in patients also taking an SSRI, SNRI or clomipramine. A low oral consumer dose is not the same exposure, and we will not pretend it is — but the mechanism is the same and the screening question is free
Injectable Glutathione Has Its Own FDA History
FDA warned in 2018 that injectable skin lightening and bleaching products may be unsafe, and in February 2019 reported seven patients who received a compounded L-glutathione injection suffering adverse events from potentially high endotoxin levels — nausea, vomiting, chills and body aches within minutes of infusion
And FDA Warned Compounders About The Raw Material
The agency specifically warned compounders not to use dietary-supplement-grade glutathione to make sterile injectables. That concern attaches to the compounding of injectable glutathione itself, not only to the cosmetic skin-lightening claims — so marketing it as "antioxidant support" does not answer it
The GLP-1 Payout Is The Largest We Have Been Offered
Semaglutide SKUs pay $375.00 and tirzepatide SKUs pay $375.00. NAD+ and sermorelin pay $225.00, glutathione $140.00, B12 $125.00, and everything else $20.00. That is the biggest per-conversion GLP-1 commission in anything we have reviewed
The Menu, Ranked By Evidence
Everything below is presented in the same reassuring typeface on their site. The support behind it is not equivalent.
| Product | How They Describe It | Where The Evidence Sits |
|---|---|---|
| Semaglutide / tirzepatide | GLP-1 and GLP-1 + GIP, compounded | Large trials for the approved drugs — but compounded is not the studied product |
| Sermorelin, NAD+ | “Growth hormone support”, “cellular energy” | No long-term human outcome trials for healthspan |
| MIC B12, L-carnitine | “Energy & fat metabolism”, “fat to fuel” | Thin evidence as weight-loss adjuncts |
| Glutathione injection | “Antioxidant support” | FDA endotoxin adverse events; warning to compounders on raw material |
| Methylene blue | “Cognitive & mitochondrial” | FDA 2011: serious, sometimes fatal serotonin syndrome with SSRIs and SNRIs |
Treat the weight-loss decision and the longevity menu as separate purchases made at different times. And if you do add something, add one thing at a time — otherwise you cannot tell what is causing what, which is exactly what a bundled menu discourages. Our Luvo Health review sets out the sermorelin and NAD+ evidence in full.
Pros & Cons
Pros
- ✓A single platform covering GLP-1s, microdosed GLP-1s and longevity products with clinician prescribing
- ✓"Prescribed and shipped within 48 hours" is a concrete, checkable service promise
- ✓Compounded status is stated on the product listings rather than hidden
- ✓Microdose semaglutide and tirzepatide options exist for patients who cannot tolerate standard titration
- ✓Needle-free NAD+ formats are offered for people who will not self-inject
- ✓Published introductory discount of up to $140 off a first order
- ✓Prices in the $79 to $199 range undercut brand GLP-1 list pricing
Cons
- ✕Sells methylene blue, which FDA has warned can cause serious and sometimes fatal serotonin syndrome with SSRIs, SNRIs, tricyclics and MAOIs
- ✕Sells injectable glutathione, a product with a documented FDA compounding-safety history including endotoxin adverse events
- ✕Compounded medicines are not FDA-approved and are reviewed by FDA for neither safety, effectiveness nor quality
- ✕Pays us $375 per GLP-1 sign-up — the largest such commission we have encountered
- ✕Sermorelin and NAD+ carry no long-term human outcome trials for healthspan
- ✕L-carnitine and MIC injections for "fat metabolism" have thin evidence as weight-loss adjuncts
- ✕We could not map each published price to a specific product from the pages we read
- ✕The affiliate programme's own product list contains misspellings of two drug names, which does not inspire confidence in its setup
- ✕The regulatory position on compounded semaglutide and tirzepatide has tightened substantially since the shortages ended
Our Verdict
2.2 / 5 — the broadest menu and the biggest commission here, including two products with active FDA safety histories.
We are going to lead with the thing we would tell a friend, because it is the only part of this review that could matter urgently. Lttl sells methylene blue, listed on its homepage as "Methylene Blue — Cognitive & mitochondrial" among its needle-free longevity products. Methylene blue has monoamine oxidase inhibiting properties — specifically it inhibits monoamine oxidase A, the enzyme that breaks down serotonin — and on 20 October 2011 the FDA issued a Drug Safety Communication warning of potentially serious and sometimes fatal interactions when it is co-administered with serotonergic psychiatric medicines, including SSRIs, SNRIs, tricyclic antidepressants and MAOIs. Serotonin syndrome runs from agitation and tremor through to hyperthermia, rigidity and, in severe cases, death. We want to be accurate about scale rather than alarming: the adverse events FDA described typically occurred at intravenous doses of 1 to 8 mg/kg administered during parathyroid surgery, mostly in patients also taking an SSRI, SNRI or clomipramine, and that is a much larger exposure than a low oral consumer dose. But the mechanism is not abolished at lower doses, the warning is not confined to surgical settings, and antidepressant use is common among people seeking weight-loss treatment. If you take one, say so before anything is dispensed and ask how the prescriber screens for it.
The second product with a specific history is injectable glutathione, sold here as "antioxidant support". There are two separate concerns and only one of them is about skin lightening. FDA warned in 2018 that injectable skin lightening and bleaching products may be unsafe, citing absence of approval and of safety evidence, and there are no published trials of injectable glutathione for that purpose. Lttl does not market it that way, and that distinction is fair. The concern that survives the distinction is about manufacture: in February 2019 FDA reported that seven patients who received an injectable drug compounded with L-glutathione experienced adverse events attributed to potentially high endotoxin levels, suffering nausea, vomiting, lightheadedness, chills, body aches and sneezing within minutes of infusion, and the agency subsequently warned compounders not to use dietary-supplement-grade glutathione to make sterile injectables. That is a warning about raw material grade and sterility in compounded injectable glutathione as such, whatever it is sold to achieve. The reasonable questions are which pharmacy compounds it, what grade of material is used, and what endotoxin testing is done on the finished product.
Around those sit the issues we have now documented across this whole batch. The GLP-1s are compounded, which means FDA reviews them for neither safety, effectiveness nor quality, and the price case that once justified that trade-off has narrowed sharply: on the same day we read their pages, NovoCare listed the FDA-approved Wegovy pill at $149 a month and the pen at $199 for new self-paying patients, and LillyDirect listed Zepbound vials from $299. Against Lttl's visible $79 to $199 range, compounded may still be cheaper at some doses — we are not pretending otherwise — but one side of that comparison has been through a regulator and the other has not. FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025, and proposed on 30 April 2026 to strike both from the 503B bulks list, comments closing 30 July 2026. Sermorelin and NAD+ have no long-term human outcome trials for healthspan, a case we set out fully elsewhere. L-carnitine and MIC injections for fat metabolism rest on thin evidence as weight-loss adjuncts. And the whole range is presented in a single uniform voice, which is precisely the problem: a customer arriving for a GLP-1 is shown a menu on which an evidence-backed molecule and a product with an active FDA safety communication look identical.
There is a real service underneath. Clinician prescribing, dispatch promised within 48 hours, microdose semaglutide and tirzepatide for patients who cannot tolerate standard titration, needle-free NAD+ formats for people who will not inject, an introductory discount of up to $140, and prices below brand list. Compounded status is stated on the listings rather than concealed. We could not map each published price to a specific product from the pages we read, and we have not guessed. One small operational note, offered as a signal rather than a substantive fault: the affiliate programme's own product list misspells both tirzepatide and sermorelin. Trivial in isolation; slightly less so when the items being listed are prescription medicines.
So the recommendation. If you take any antidepressant or other serotonergic medicine, raise the methylene blue interaction before anything else and do not let it be dispensed until someone has reviewed your full medication list. Price the FDA-approved GLP-1 options before the compounded ones, and check insurance and your employer's formulary before either. Treat the longevity menu as a completely separate decision from the weight-loss one, made on a different day; if you add anything, add one item at a time so you can attribute effects. Get baseline bloods through your own clinician before anything acting on the growth hormone axis. And tell your regular prescriber everything you are taking, because the specific hazard these platforms create is one clinician not knowing what another has prescribed — which is the one risk on this page you can eliminate yourself, for nothing. Our disclosure, which should colour all of it: $375 per semaglutide or tirzepatide sign-up, $225 on NAD+ and sermorelin, $140 on glutathione, $125 on B12. That is the largest GLP-1 payout we have been offered by any merchant, and every word of advice in this paragraph reduces it to zero.
Visit LttlFrequently Asked Questions
What is the methylene blue concern?
It is a genuine, documented drug interaction, and it is the reason this review leads where it does. Lttl lists "Methylene Blue — Cognitive & mitochondrial" among its needle-free longevity products. Methylene blue is a real drug with legitimate approved uses, but it also has monoamine oxidase inhibiting properties: specifically it inhibits monoamine oxidase A, the enzyme responsible for breaking down serotonin. On 20 October 2011 the FDA issued a Drug Safety Communication warning of potentially serious and sometimes fatal interactions when methylene blue is co-administered with serotonergic psychiatric medications — selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors and other psychiatric drugs with serotonergic effects. The syndrome in question, serotonin syndrome, ranges from agitation, tremor and sweating through to hyperthermia, rigidity and death in severe cases. Now the fairness, because it matters and we are not trying to frighten anyone. The adverse events FDA described typically arose at intravenous doses between 1 and 8 mg/kg given during parathyroid surgery, mostly in patients concurrently taking an SSRI, SNRI or clomipramine. That is a substantially larger exposure than a low oral consumer dose, and we are not claiming the risks are identical. But the mechanism does not disappear at lower doses, the FDA warning is not qualified to surgical settings, and antidepressant use is very common among people seeking weight-loss treatment. So the practical instruction is simple and costs nothing: if you take any antidepressant, tell the prescriber before methylene blue is dispensed, and ask specifically how they are screening for this interaction.
And the injectable glutathione?
It has a specific FDA safety history that the "antioxidant support" framing does not address. Two threads. The first is the cosmetic one: injectable glutathione is widely sold internationally for skin lightening, and in 2018 FDA warned that injectable skin lightening and skin bleaching products may be unsafe, noting the absence of approval and of safety evidence. There are no published clinical trials evaluating injectable glutathione for skin lightening and no established dosing guidance. Lttl markets it as "antioxidant support" rather than for skin lightening, and we should be fair about that distinction. The second thread, though, applies regardless of the indication, and it is the one that concerns us more. In February 2019 FDA reported that seven patients who received an injectable drug compounded with L-glutathione suffered adverse events attributed to potentially high endotoxin levels, experiencing nausea, vomiting, lightheadedness, chills, body aches and sneezing within minutes of infusion. FDA subsequently warned compounders not to use dietary-supplement-grade glutathione to make sterile injectable products. That is a warning about the manufacture of injectable glutathione itself — about raw material quality and sterility — not about what it is sold to achieve. So if you are considering it here, the questions to ask are which pharmacy compounds it, what grade of raw material is used, and what endotoxin testing is performed on the finished product. Those are reasonable questions and a good provider will answer them.
What else do they sell?
A broad catalogue spanning three categories, with the evidence base thinning as you move down it. On weight loss: compounded semaglutide and compounded tirzepatide, plus microdose versions of both, described as "low-dose GLP-1" and "low-dose GLP-1 + GIP". On longevity, by injection: sermorelin for "growth hormone support", NAD+ injectable for "cellular energy", MIC B12 for "energy & fat metabolism", L-carnitine for "fat to fuel conversion", and glutathione for "antioxidant support". Needle-free: NAD+ nasal spray, NAD+ oral liquid described as liposomal, and methylene blue for "cognitive & mitochondrial". Prices visible on their homepage ranged from $79 to $199, with an advertised introductory offer of "Up to $140 off on your first order" and a promise of being "Prescribed and shipped within 48 hours" — we were not able to map each price to a specific product from the pages we read, so treat that range as indicative. Ranking honestly by evidence: the GLP-1 molecules are supported by large randomised trials, though the compounded versions of them are not the studied products. Sermorelin and NAD+ have no long-term human outcome trials for healthspan, a point we set out at length in our review of another provider selling both. L-carnitine and MIC injections for fat metabolism have thin evidence as weight-loss adjuncts. Methylene blue and injectable glutathione carry the specific FDA concerns described above. That is a catalogue where the marketing is uniform across products whose underlying support is anything but.
How much are you paid, and does it show?
$375 per GLP-1 sign-up, which is the largest such payout we have encountered, and yes, you should factor it in. The published schedule is: semaglutide SKUs $375.00, tirzepatide SKUs $375.00, NAD+ SKUs $225.00, sermorelin SKUs $225.00, glutathione SKUs $140.00, B12 SKUs $125.00, and a $20.00 default on everything else. For scale, across the forty merchants in this batch the typical commission has been a few dollars — two to ten per cent of an order. This one pays $375 for a single conversion, and $140 for signing someone up to a product with the FDA compounding history described above. We have made a habit in these reviews of publishing the commission prominently rather than burying it, and this is the clearest case for doing so: when the payout on a single sign-up exceeds most people's monthly grocery bill, the reader is entitled to assume that every enthusiastic review they encounter, ours included, was written by someone with a substantial reason to be enthusiastic. That is also why we have spent this review on drug interactions rather than on the 48-hour shipping. One small thing worth mentioning because it speaks to operational care: the programme's own product list misspells two drug names, rendering tirzepatide and sermorelin incorrectly. It is a trivial error in itself. It is a slightly less trivial signal when the products in question are prescription medicines.
Should I buy compounded GLP-1s here?
Price the FDA-approved options first, as we now say in every review of a compounded provider, because the arithmetic has changed. Compounded means not FDA-approved: the agency reviews these preparations for neither safety, effectiveness nor quality, and no compounded product has been through the trials that produced the published results for the approved medicines. For years the trade-off was defensible on price, when brand list prices sat above a thousand dollars a month. That is no longer the comparison. Checked on 8 August 2026 from the manufacturers' own pages, NovoCare listed the FDA-approved Wegovy pill at $149 a month for the 1.5mg or 4mg doses and the Wegovy pen at $199 a month for new self-paying patients through 31 December 2026, while LillyDirect listed Zepbound single-dose vials from $299 for 2.5mg, $399 for 5mg and $449 for 7.5mg through 15mg refilled within 45 days. Against Lttl's $79 to $199 range the compounded route may still be cheaper for some doses, particularly tirzepatide, and we would not pretend otherwise — but the gap is nothing like it was, and one side of it has been reviewed by a regulator. There is also a regulatory clock: FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025, and on 30 April 2026 proposed excluding both molecules from the 503B bulks list, with comments closing 30 July 2026. Lawful compounding lanes remain and we allege nothing about this company, but that is the direction of travel for a treatment you may want for years. Check insurance and your employer's formulary before any of it.
What should I ask before signing up?
Six questions, and the first one is not optional if you take any psychiatric medication. One: I take an antidepressant — how do you screen for the methylene blue interaction, and will a prescriber review my full medication list before anything is dispensed? Two: for any injectable, which pharmacy compounds it, is it 503A or 503B, and what testing is done on the finished product — a question that matters most for the glutathione. Three: is this product FDA-approved or compounded, and if compounded, what documented clinical reason applies to me rather than to customers generally? Four: what is the total cost at the maintenance dose I am likely to reach, not the introductory one, and does the "up to $140 off" apply once or ongoing? Five: can I cancel at any time, without notice period or penalty, and how? Six: what is the plan for stopping, and what would make you recommend it? Beyond the provider, two things to do independently. Get baseline bloods through your own clinician before starting anything acting on the growth hormone axis — IGF-1 at minimum for sermorelin. And tell your regular prescriber every single thing you are taking, including anything bought from a telehealth service, because the interaction risks discussed on this page only exist where one clinician does not know what another has prescribed. That is the failure mode these platforms create, and it is the one you can close yourself for free.
Is any of this useful if I only want weight-loss help?
Yes, and the useful part is knowing what to decline. If you come here for a GLP-1, you will be presented with a menu that also contains sermorelin, NAD+ in three formats, L-carnitine, MIC B12, glutathione and methylene blue, all wrapped in the same clinical-sounding language about energy, metabolism and ageing well. The evidence behind those products is not remotely equivalent to the evidence behind the GLP-1 you came for, and the commission schedule shows the company earns well across the whole range. The disciplined approach is to treat the weight-loss decision and the longevity menu as entirely separate purchases, made at different times, with different questions. For the actual problems GLP-1 patients face, the interventions with the best support remain unglamorous and mostly free: resistance training at least twice a week and adequate protein for preserving lean mass, deliberate hydration because appetite suppression blunts thirst and you lose the water that came from food, and fibre and fluid for constipation. None of those are sold here. If you want to spend money productively alongside a GLP-1, spend it on a dietitian consultation or a gym membership before an injectable antioxidant. And if you do add anything, add one thing at a time so that you can tell what is causing what — which is impossible if you start four products in the same week, and is exactly what a bundled longevity menu encourages.
What is your verdict?
2.2 out of 5 — the broadest catalogue and the biggest commission in this batch, attached to two products carrying specific FDA safety histories. Start with the thing we would want a friend to know. Lttl sells methylene blue as a "cognitive & mitochondrial" product. Methylene blue inhibits monoamine oxidase A, and on 20 October 2011 FDA issued a Drug Safety Communication warning of serious and sometimes fatal serotonin syndrome when it is combined with serotonergic psychiatric medicines including SSRIs, SNRIs, tricyclics and MAOIs. In fairness, the reported cases were largely at intravenous doses of 1 to 8 mg/kg in surgical settings, which is not a low oral consumer dose, and we say so plainly rather than overstating. But antidepressant use is common among people seeking weight-loss treatment, the mechanism is not dose-abolished, and the screening question costs nothing. It belongs at the top of this page rather than in a footnote. Second, injectable glutathione: FDA warned in 2018 that injectable skin lightening products may be unsafe, reported in February 2019 that seven patients suffered adverse events from a compounded L-glutathione injection with potentially high endotoxin levels, and warned compounders against using dietary-supplement-grade glutathione for sterile injectables. Marketing it as antioxidant support does not answer a manufacturing concern. Around those sit the familiar issues: compounded GLP-1s that are not FDA-approved at a moment when NovoCare sells the Wegovy pill at $149 and LillyDirect sells Zepbound vials from $299; sermorelin and NAD+ with no long-term outcome trials; L-carnitine and MIC injections with thin evidence; and a programme that pays us $375 for a GLP-1 sign-up and $140 for a glutathione one. There is a real service here — clinician prescribing, 48-hour dispatch, microdose options for people who cannot tolerate titration, prices below brand list. But a platform that puts a genuinely evidence-based medicine on the same menu as products with active FDA safety communications, in the same reassuring typeface, is asking the customer to do triage the platform should have done. Our disclosure: up to $375 per conversion, and nothing at all if you follow this review and ask the six questions first.
Tell Them About Your Antidepressant.
Methylene blue inhibits monoamine oxidase A, and FDA has warned of serious serotonin syndrome with SSRIs and SNRIs since 2011. Raise it before anything is dispensed — and price the FDA-approved GLP-1 options first.
Visit LttlCompare Other GLP-1 Providers
See how other telehealth providers stack up.
Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →Amazon One Medical
Brand-Name, No CompoundingFDA-approved Wegovy, Zepbound and Foundayo from $149/month cash, $25 with insurance and $50/month for eligible Medicare members — the first mainstream route to approved medication at prices that compete with compounded. We earn no commission from it
Read Review →CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →BeyondMD
Top RatedBoard-certified physician-led care with comprehensive medical oversight
Read Review →Medical Disclaimer: This page is informational and is not medical advice, a diagnosis, or a recommendation for or against any treatment or provider. Serotonin syndrome is a potentially life-threatening condition; symptoms can include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity or twitching, sweating, diarrhoea, and in severe cases high fever, seizures and irregular heartbeat, and it constitutes a medical emergency requiring immediate care. Anyone taking an SSRI, SNRI, tricyclic antidepressant, MAOI, triptan, tramadol, lithium, St John's wort or any other serotonergic agent should discuss this with a clinician and pharmacist before taking methylene blue in any form, and should not stop a prescribed antidepressant in order to take it. Compounded medications are not FDA-approved and are reviewed by the FDA for neither safety, effectiveness nor quality. GLP-1 receptor agonists are prescription medicines with serious potential risks; in animal studies semaglutide and tirzepatide caused thyroid C-cell tumours, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Sermorelin acts on the growth hormone axis and may be contraindicated in active malignancy. Injectable products carry infection and contamination risks additional to those of the active ingredient. Statements about the evidence base for sermorelin, NAD+, L-carnitine and MIC injections are general summaries and are not claims made by the retailer. Only a licensed clinician with your full history and medication list can determine whether any of these treatments is appropriate. Do not start, stop or change any prescribed medication on the basis of this page, and always tell every clinician treating you about everything you take, including products bought online. Prices quoted are the seller's published figures on the date stated and change without notice. Consult a licensed clinician before starting or changing any treatment.
Date reviewed: 8 August 2026. Lttl's product range was read from lttl.com on that date, which listed under Weight Loss 'Semaglutide GLP-1 · Compounded' and 'Tirzepatide GLP-1 + GIP · Compounded'; under Longevity injectables 'Sermorelin Growth hormone support', 'NAD+ Injectable Cellular energy', 'MIC B12 Energy & fat metabolism', 'L-Carnitine Fat to fuel conversion' and 'Glutathione Antioxidant support'; under Needle-Free 'NAD+ Nasal Spray', 'NAD+ Oral Liquid Liposomal oral NAD+' and 'Methylene Blue Cognitive & mitochondrial'; and under Microdose 'Microdose Semaglutide Low-dose GLP-1' and 'Microdose Tirzepatide Low-dose GLP-1 + GIP'. The homepage also displayed 'Prescribed and shipped within 48 hours' and 'Up to $140 off on your first order'. Prices visible on that page were $79, $109, $129, $140 and $199; we were unable to map individual prices to specific products from the pages we read and therefore report the range only. Methylene blue: the FDA issued Drug Safety Communications on 20 October 2011 warning of potentially serious, and in some cases fatal, interactions when methylene blue or linezolid are co-administered with serotonergic psychiatric medications including SSRIs, SNRIs, tricyclic antidepressants and MAOIs, both agents having monoamine oxidase inhibiting properties and specifically inhibiting monoamine oxidase A. Reported adverse events typically occurred at intravenous methylene blue doses between 1 mg/kg and 8 mg/kg administered during parathyroid surgery, with a majority of cases involving concomitant SSRI, SNRI or clomipramine use; we state that dose context explicitly because it is material to how the risk should be weighed at consumer oral doses, which have not been the subject of the reported case series. Glutathione: the FDA published a warning in April 2018 that injectable skin lightening and skin bleaching products may be unsafe, citing absence of approval and of safety evidence; in February 2019 the FDA reported an incident in which seven patients who received an injectable drug compounded with L-glutathione experienced adverse events attributed to potentially high levels of endotoxins, with symptoms including nausea, vomiting, lightheadedness, chills, body aches and sneezing within minutes of infusion; and the FDA has warned compounders not to use dietary-ingredient or dietary-supplement-grade glutathione to compound sterile injectable drugs. Reporting also indicates there are no published clinical trials evaluating injectable glutathione for skin lightening and no published guidelines for dosing or duration. Lttl markets glutathione as 'antioxidant support' and not for skin lightening; we note that distinction and rely on the compounding and endotoxin concerns, which are independent of the marketed indication. Comparator prices were read the same day from the manufacturers' own self-pay pages: NovoCare listed the Wegovy pill at $149 per month for the 1.5 mg or 4 mg doses and the Wegovy pen at $199 per month for new self-paying patients through 31 December 2026; LillyDirect listed Zepbound single-dose vials from $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg refilled within 45 days. Regulatory background: the FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025, and on 30 April 2026 proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with comments closing 30 July 2026. None of this constitutes an allegation that Lttl or any pharmacy it works with has breached any law or regulation, and we identified no FDA warning letter naming the company. Limitations: we did not create an account, complete an intake, consult a clinician, receive any product or test the cancellation process, and we make no independent assessment of clinical quality, prescriber licensure coverage, screening practices, shipping or customer service; in particular we do not know how the company screens for the methylene blue interaction, and readers should ask. Katalys offer #1619 lists commissions of $375.00 on semaglutide SKUs, $375.00 on tirzepatide SKUs, $225.00 on NAD SKUs, $225.00 on sermorelin SKUs, $140.00 on glutathione SKUs, $125.00 on B12 SKUs and a $20.00 default; that schedule as supplied to us misspells 'Tirezpatide' and 'Semorelin'.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This programme pays $375.00 on semaglutide and tirzepatide SKUs, $225.00 on NAD+ and sermorelin, $140.00 on glutathione, $125.00 on B12 and $20.00 by default — the largest GLP-1 per-conversion payout of any merchant we have reviewed, against a typical few dollars elsewhere in this batch. Our recommendations here are to raise the methylene blue interaction before purchase, to price the FDA-approved GLP-1 options first, to check insurance, and to treat the longevity menu as a separate decision, all of which reduce or eliminate what we earn. This does not influence our editorial content or review ratings.